Colorectal cancer is a major public health problem internationally and in the United Kingdom, where it is the third most common cancer and the second leading cause of cancer death. ([@bib9]; [@bib5]) Randomised trials have shown that screening using guaiac faecal occult blood testing (gFOBt) significantly reduces mortality from colorectal cancer. ([@bib12]) In 2006 the English NHS Bowel Cancer Screening Programme (BCSP) introduced two-yearly gFOBT screening and now offers it to all individuals aged 60--74 years.

For population cancer screening to achieve its intended public health impact, high levels of participation are necessary. National variations in screening uptake, examined between 2006 and 2009 found that uptake overall was 54% and that this varied from 61% in the least deprived to 35% in the most deprived areas of the country. ([@bib26]) The stepwise relationship between socioeconomic group and health whereby more socioeconomically advantaged individuals have better health and better access to health care is well known. ([@bib10]) The costs of inequalities are therefore borne not only by those at the bottom of the socioeconomic hierarchy but at every level. Interventions that target the most disadvantaged subgroups only, or which aim to narrow the gap between the most and least disadvantaged, underestimate the pervasive effect across the socioeconomic hierarchy and exclude those in need in the intermediate socioeconomic groups.

Participants with a positive gFOBt result are invited for further investigation (usually colonoscopy). Fortunately, the low uptake and striking socioeconomic gradients are not seen in attendance at colonoscopy. Overall colonoscopy uptake is 83% with little variation between socially advantaged and disadvantaged areas (86--80%). ([@bib18]) The high follow-up and low socioeconomic gradient in uptake of colonoscopy indicates that addressing the gFOBt uptake gradient should improve subsequent uptake of effective treatment and therefore contribute to reducing inequalities in survival. ([@bib7]).

In order to address the UK Government\'s commitment to reduce health inequalities, ([@bib11]) we undertook the ASCEND-randomised controlled trials research programme. In ASCEND we designed four interventions aimed at reducing the socioeconomic gradient in bowel screening participation without compromising uptake overall. The interventions were: a simplified version of the information leaflet aimed at individuals with low literacy or numeracy skills; a narrative information leaflet including experiences of people who had participated in the BCSP; general practitioner endorsement (GPE) of the invitation to participate (80% of GP practices nationally agreed to endorse the programme using the statement 'your GP practice, name of practiceę supports the Bowel Cancer Screening Programme\' on invitation letters); and an enhanced reminder letter (ER), replacing the usual reminder sent to those who had not returned a kit within 4 weeks.

The summary results of the four national cluster-randomised controlled trials (RCTs) of these interventions are provided elsewhere. ([@bib27]) In this paper, we report details of the impact of the national cluster-RCT of the enhanced reminder on the socioeconomic gradient in BCSP uptake and its cost.

Materials and Methods
=====================

Intervention
------------

The value of sending reminders to improve screening uptake is well established ([@bib4]) and all individuals who are sent a bowel cancer screening kit as part of the BCSP are sent a reminder letter if the kit is not returned within 4 weeks. Research on breast screening attendance suggests that reminders maybe helpful in increasing uptake in low-income women, ([@bib6]) particularly if the content of the reminder addresses barriers to screening participation, which are known to be socially graded. Evidence has demonstrated that low awareness of bowel cancer is significantly more prevalent among more deprived groups and that individuals from lower socioeconomic groups tend to perceive the barriers to screening to be higher and the benefits of screening to be lower than high socioeconomic groups. ([@bib20]; [@bib28]) One particular barrier to screening that has been extensively studied and found to be an important predictor of colorectal cancer screening uptake is perceived risk ([@bib23]; [@bib24]; [@bib21]). We therefore developed an enhanced reminder letter, which aimed to target low awareness of bowel cancer and, in addition, specifically addressed inaccurate risk perceptions. Increasing age is a risk factor and pertinent characteristic of all screening invitees, regardless of their socioeconomic group and one that could be simply and directly stated. We designed the enhanced reminder letter in collaboration with the Health & Social Care Information Centre (HSCIC) to ensure that the enhancement we developed would fit into the usual letter without disrupting the format and thus without incurring any additional costs to BCSP. We also obtained feedback from focus group participants who had been convened to explore reasons for non-uptake of bowel cancer screening. ([@bib19]) The final version of the enhanced reminder included two additions to the usual letter: a banner reading 'A reminder to you\' at the start of the letter and a brief restatement of the screening offer at the end of the letter.

The control intervention was the usual reminder letter. The text of both reminder letters is given in the web appendix. ([Supplementary files 1 and 2](#sup1){ref-type="supplementary-material"}).

Randomisation and blinding
--------------------------

The study was carried out within the routine activity of the BCSP. The BCSP in England is organised within five regional hubs (Midlands and Northwest; Southern; London; Northeast; and Eastern), all of which participated in this trial. The intervention period of this study overlapped with our trial of GPE of the offer of screening, so a proportion of individuals were in both trials (see results below).

The invitation and reminder system of the Programme did not permit randomisation of individual invitees. Instead, we randomised days within hubs. That is, for a given date within a given hub, all individuals who were due to be sent a reminder on that date were randomised to the same trial arm, either the usual reminder or enhanced reminder.

Blinding of individuals was not possible, but the possibility of biasing participation was minimal owing to the lack of direct contact with participants. Individuals were unaware of a comparator condition unless a member of their household received a reminder letter during the study period that contained different information materials. Hubs however were effectively 'blind\' to the randomisation schedule, which was sent only to HSCIC. To assure quality, Hubs reported back to the Trial Office whether the intervention was included and this was checked against the randomisation schedule by the research team.

Outcome measures and costs
--------------------------

The outcome measure (adequately screened) was defined as the return of a gFOBt kit within 18 weeks of the initial invitation that led to a 'definitive\' test result of either 'normal\' (i.e., no further investigation required) or 'abnormal\' (i.e., requiring referral for further testing, usually colonoscopy) by the date of data extraction. The 18-week time limit coincided with the date on which the BCSP closes a screening episode to a non-responder. The primary analysis addressed heterogeneity of the effect of the enhanced reminder by socioeconomic status quintile.

Socioeconomic status was measured using the Index of Multiple Deprivation (IMD) 2010 score associated with each individual\'s home address ([@bib8]) IMD, a well validated marker of socioeconomic status, comprises 38 separate indicators, organised across seven distinct domains (Income, Employment, Health and Disability, Education Skills and Training, Barriers to Housing and Other Services, Crime and Living Environment). These are combined, using appropriate weights, to calculate the IMD for every Lower Layer Super Output Area (LSOA) in England. Each LSOA covers ∼1500 individuals. Each individual\'s postcode was linked to the relevant LSOA. The IMD can be used to rank every LSOA in England according to their relative level of deprivation. IMD was classified in five categories based on national quintiles, ([@bib27]) with 1 representing the least deprived and 5 the most deprived. In addition we estimated the overall effect of the enhanced reminder intervention on participation rates.

We calculated the costs of modifying the BCSP IT system to incorporate the enhanced reminder. This was based on the actual cost charged to the study to modify the reminder letter.

Statistical considerations
--------------------------

Data were analysed by logistic regression with conservative variance estimates to take account of randomisation by hub-day clusters. (Huber, 1967; [@bib29]) including interaction tests for heterogeneity of effect by IMD quintile. We further adjusted for age, sex, hub and screening episode type (first ever screening episode, prevalent episode in previous non-participant or incident episode in previous participant). In formal testing for heterogeneity of effects of age, sex, hub and screening episode type by socioeconomic status, we used the continuous IMD score to increase statistical power.

We calculated average marginal effects (which give the effect on absolute percentage uptake adjusted for other factors) and used these to predict the impact of the enhanced reminder on the detection of colorectal adenomas and cancer in the NHS BCSP.

Sample size was calculated using the method of Brentnall *et al*, ([@bib3]) to give 90% power to detect as significant at the 5% level a heterogeneity of the effect of the intervention by IMD quintile such that the absolute increase in participation in the most deprived quintile was 5 percentage points and the increase in the least deprived was 1 percentage point. This indicated that 46 000 individuals would be required. With ∼1500 reminders sent per hub per working day, this would have required 31 hub-day clusters. To take account of the additional variation generated by the cluster randomisation, we randomised 100 hub-days, the 20 working days from Monday 8th July 2013 to Friday 2nd August 2013, in each of the five hubs. Owing to a protocol deviation, data from one hub on one day (8th July) could not be used. This gave a total of 99 randomisation units and 168 480 individuals randomised, 78 067 to enhanced reminder and 90 413 to the usual reminder.

Study approvals
---------------

Consent forms were not required in this study because the interventions took place as part of individuals\' usual communication from the BCSP.

Ethical Approval was obtained from the UK National Research Ethics Service, London---Harrow Ethics Committee, Reference number 12/LO/1396 prior to commencement of the study. Local Ethics Committee approval was not required as this was a national trial incorporated within the BCSP. Site approval was obtained at each of the Bowel Cancer Screening Programme Hubs.

Patient involvement
-------------------

Patient and third sector representatives were involved in the planning and development of all four interventions examined in the ASCEND trials and a bowel cancer patient was a co-applicant on the study. The research team also undertook patient and public engagement activities, presenting information about the study at conferences and to other groups. ([Supplementary file 3](#sup1){ref-type="supplementary-material"}).

Results
=======

The RCT included 168 480 individuals from 99 clusters.

[Table 1](#tbl1){ref-type="table"} describes the characteristics of the study individuals by trial arm. The arms were well balanced with respect to sex. For other variables, there were slight imbalances between trial arms, presumably induced by between-hub between-day differences in individuals sent reminders. The proportion of individuals decreased as deprivation increased in both arms. This is because individuals were categorised by IMD quintiles based on the national distribution of scores, rather than by the distribution of scores in our sample (i.e., not 20% in each quintile). The enhanced reminder arm was characterised by older individuals, a higher proportion of prevalence screens in previous non-participants and fewer first ever screening episodes.

[Table 2](#tbl2){ref-type="table"} shows the percentages and absolute numbers adequately screened by trial arm, stratified in turn by sex, age, screening episode type, hub and IMD quintile. Overall, there was 0.7 percentage point higher participation rate with the enhanced reminder (25.8% compared with 25.1% uptake after the usual reminder). This was not significant in the univariate analysis, but was significant when adjusted for age, sex, hub and screening episode type (adjusted OR=1.07, 95% CI 1.03--1.11, *P*=0.001, [Table 3](#tbl3){ref-type="table"}), from 25.1 to 25.8% uptake. In both trial arms and overall, higher participation rates were observed for females, younger individuals, incident screens (i.e., in persons who had previously participated), the Southern hub and the less-deprived quintiles.

In terms of the relationship of this trial to the GPE trial, the unadjusted OR for uptake associated with the enhanced reminder in those not in the GPE trial was 1.06, higher than the overall unadjusted OR of 1.04. Furthermore, the OR associated with receiving the enhanced reminder adjusted for GPE trial status was 1.04, identical to the unadjusted OR.

There was a significant interaction between trial arm and IMD quintile after adjustment (*P*=0.005). [Table 4](#tbl4){ref-type="table"} shows the adjusted ORs from multivariate analysis stratified by IMD quintile. Within the most deprived quintile, the odds of returning a completed kit were 11% higher in the enhanced reminder arm (absolute increase from 13.3 to 14.1%). There was no difference in the odds of returning a completed kit within the least deprived quintile. Odds ratios were similar across the three most deprived quintiles, ranging from 1.09 to 1.13 and in each case were significantly higher in the enhanced reminder group compared with the usual reminder group.

[Table 3](#tbl3){ref-type="table"} shows the multivariate adjusted effects of trial arm, sex, age, screening episode type, hub and IMD quintile, with each factor adjusted for all others in the logistic regression. The differences in participation by trial arm, sex, screening episode type, hub and IMD quintile were all statistically significant.

[Table 5](#tbl5){ref-type="table"} gives the effect of the enhanced reminder within subgroups of sex, age, hub and screening episode type, and the test for interaction of the intervention with IMD quintile. The effect of the enhanced reminder was stronger in the London and Northeast hubs (although the effect was not significant), and the interaction between trial arm and IMD quintile was strongest in the Southern hub.

A 7% increase in the odds of screening across all individuals in the adjusted model was associated with predictive margins (adjusted average probabilities of uptake) of 0.259 (95% CI 0.255--0.265) in the enhanced reminder group and 0.250 (95% CI 0.248-- 0.253) in the usual reminder group. This implies a 3.6% relative increase in the probability of screening (0.259/0.250) and a 0.9 percentage point absolute increase (0.259--0.250; the average marginal effect). The adjusted effect was larger than the unadjusted (see discussion below). In the 2013/14 fiscal year the number of reminder letters sent in the BCSP in England was 2 144 277. (BCSSN, 2015) An average marginal effect of 0.9 percentage points (0.009) suggests that if the enhanced reminder were implemented nationally, then 19 298 extra people each year might be screened. In 2013/14 the positivity rate among the screened population was 1.84%. ([@bib2]) Evidence suggests that 83% of people with a positive test result attend a specialist screening practitioner clinic and undergo further investigation, and among those who go on to have further investigations, 10.1% will have a colorectal cancer and 27.2% will have colorectal adenomatous polyps classed as intermediate or high risk requiring further investigation. ([@bib17]) Hence, if the enhanced reminder were implemented nationally it might detect up to an additional 80 people (19 298\*0.0184\*0.83\*0.272) with polyps classed as high or intermediate risk, and 30 people (19 298\*0.0184\*0.83\*0.101) with a colorectal cancer in England each year.

The enhanced reminder incurred a one-off cost of £78000 to modify the usual reminder within the NHS BCSP. This would not need to be incurred again if the enhanced reminder were implemented. No additional costs were incurred per person invited to screening, hence the average marginal cost per additional enhanced reminder was zero.

Discussion
==========

The addition of simple, brief messages to the usual BCSP reminder letter increased the odds of participation in the Programme by 11% among those living in the most deprived areas (in absolute terms from 13.3 to 14.1% uptake) and by 7% (from 25.1 to 25.8% uptake) overall. As a result of our research design, whereby the intervention was embedded within the BCSP\'s usual practice, these benefits can be realised immediately, with no operational changes required and at no additional cost. We estimate the enhanced reminder can result in up to 80 more people with high or intermediate risk polyps and 30 additional colorectal cancers detected in England each year. The stronger effect of the enhanced reminder in low socioeconomic status groups is reflected in the corresponding stronger effect suggested in London and the Northeast.

A major strength of our trial is its national coverage and the large sample size yielding substantial statistical power to detect small differences in uptake between subgroups. The trial was specifically powered to detect socioeconomic differences in the effect on uptake, allowing us to draw conclusions about the demonstrated differences between IMD quintiles, but not about the relevance of the other statistically significant differences found. This is, to our knowledge the first trial specifically designed to examine effects across the entire socioeconomic gradient and the first intervention to result in a slightly greater proportional effect in more deprived populations. Our results could be argued to satisfy Victora\'s 'inverse equity\' hypothesis, which predicts that newly implemented public health interventions initially reach those of higher socioeconomic status and only later affect the poor when the affluent have achieved new minimum achievable levels for morbidity, a hypothesis that has been confirmed internationally. ([@bib25]).

Until recently, studies that addressed socioeconomic inequalities in uptake tended to focus specifically on under-served groups. ([@bib1]) Even if they are successful, these initiatives do not benefit the larger population in need outside the targeted group. In addition, they are often highly intensive (e.g., by providing community support workers) and are therefore impractical for wide-scale implementation. More recently less-resource-intensive interventions such as text message reminders have been found to increase attendance at breast screening appointments ([@bib15]) and their effectiveness in improving uptake of gFOBT screening in the BCSP is currently being examined. ([@bib13]).

We were unable, for logistical reasons, to use individual randomisation and this led us to implement cluster randomisation as the strongest alternative. If anything, this led to an underestimation of the effect. This can be seen if one considers the overall absolute difference in participation between the enhanced and usual reminder arms (0.7%) along with the differences observed within individual hubs, of 0.6% (Midlands and Northwest), 0.9% (Southern), 1.5% (London), 1.5% (Northeast) and 0.4% (Eastern). The average of the latter, weighted by study population in each hub is 0.9%, larger than the overall unadjusted effect. This probably reflects a greater and more systematic variation between clusters than was anticipated when the trial was designed. This is also almost certainly the reason for a larger and more significant multivariate adjusted effect than the unadjusted. Ideally, future studies should be randomised at individual level, and if this is not possible, stratified analyses, conditional on hub and possibly other covariates should be planned *a priori.*

Although we used an area-based measure of deprivation, which may underestimate individual effects, IMD quintile has been demonstrated ability to explain socioeconomic variations in bowel cancer screening uptake at the LSOA level. ([@bib26]) IMD is widely used, enabling direct comparison of our results with other studies.

There may have been some individuals who received the usual or enhanced reminder after sending in a kit. This would have the tendency to underestimate the effect of the enhanced reminder. It is also worth noting that the enhanced reminder arm of the study had older individuals and a greater proportion of prevalent screening invitations. These would be likely to attenuate the effect of the enhanced reminder because the enhanced reminder arm contained a higher proportion of previous non-responders who are much less likely to respond to a screening invitation compared with first timers and people who have already participated in a previous round. ([@bib22]; [@bib16]) As can be seen from [Table 2](#tbl2){ref-type="table"}, the previous non-responders had an overall participation rate of 6% compared with 59% in previous responders. Thus the true increase in participation with the enhanced reminder is likely to be greater than reported here.

We used published data from 2013/14 to estimate the additional number of colorectal cancers and high or intermediate risk polyps detected annually by implementing the enhanced reminder. These figures vary between geographical regions and change over time. For example, in common with all successful population screening programmes, the proportion of cases identified by the Programme falls as the proportion of individuals in the population who have been repeatedly screened increases.

Contamination between study groups could have occurred if, for example, household members were randomised to different arms of the trial during the 4-week study period. Although this limitation is noted, it would also have applied to a parallel randomised trial. It is also possible that concurrent initiatives affected uptake. We therefore surveyed the number and location of interventions occurring during the four national trials (of which enhanced reminder was one) and identified nine research studies and 27 health promotion activities focusing on bowel cancer screening occurring within the time frame of the trials. However, it is unlikely that they influenced our results because the chance of these initiatives occurring on the same alternate days as enhanced reminder would be negligible.

In conclusion, this large national trial demonstrated that a simple, brief message to enhance awareness of bowel cancer and clarify the objective of cancer screening, disseminated as part of routine practice by the BCSP, achieved a greater proportional effect in more deprived populations. This enhanced reminder incurred a small cost to implement and will incur only minimal maintenance costs if rolled out into routine practice. It could identify 80 more individuals with high or intermediate risk polyps and 30 additional bowel cancers in England each year.
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###### Distributions of the study population in each arm of the trial by sex, age, screening episode type, hub and IMD quintile

                                                 **Usual reminder**   **Enhanced reminder**   **Total**                   
  --------------------------------------------- -------------------- ----------------------- ----------- ------ --------- ------
  **Sex**                                                                                                                 
  Male                                                 46 839                 51.8             40 320     51.7   87 159    51.7
  Female                                               43 574                 48.2             37 747     48.4   81 321    48.3
  **Age (years)[a](#t1-fn4){ref-type="fn"}**                                                                              
  \<65                                                 46 771                 51.7             38 390     49.2   85 161    50.6
  65--69                                               27.781                 30.7             24 870     31.9   52 651    31.2
  70--74                                               15 861                 17.5             14 807     19.0   30 668    18.2
  **Screening episode type**                                                                                              
  Prevalent first time                                 21 271                 23.5             14 483     18.5   35 754    21.2
  Incident                                             25 813                 28.5             23 722     30.4   49 535    29.4
  Prevalent previous non responder                     43 329                 47.9             39 862     51.1   83 191    49.4
  **Hub**                                                                                                                 
  Midlands and NorthWest                               25 490                 28.2             22 051     28.2   47 541    28.2
  Southern                                             23 107                 25.6             19 131     24.5   42 238    24.5
  London                                               10 385                 11.5             10 809     13.8   21 194    13.8
  North East                                           12 796                 14.1             12 291     15.7   25 087    15.7
  Eastern                                              18 635                 20.6             13 785     17.7   32 420    17.7
  **IMD quintile[b](#t1-fn5){ref-type="fn"}**                                                                             
  1 (least deprived)                                   18 928                 20.9             15 933     20.4   34 861    20.7
  2                                                    19 446                 21.5             16 594     21.3   36 040    21.4
  3                                                    18 286                 20.2             16 092     20.6   34 378    20.4
  4                                                    16 853                 18.6             14 679     18.8   31 532    18.7
  5 (most deprived)                                    16 489                 18.2             14 441     18.5   30 930    18.4
  Not known                                             411                    0.4               328      0.4      739     0.4
  Total                                                90 413                                  78 067            168 480     

'Prevalent first time\': people being invited for the first time.

'Incident\': invitations to people who have participated in screening previously.

'Prevalent previous non responder\': people invited to be screened at least once previously, who have never responded.

Some individuals were invited just before their 60th birthday

Index of multiple Deprivation: quintile based on national distributions using pre-defined national cut-offs.

###### Numbers and percentages of individuals adequately screened, by trial arm and sex, age, screening episode type, hub and IMD quintile

                                     **Number (%) adequately screened**                   
  ---------------------------------- ------------------------------------ --------------- ---------------
  **Sex**                                                                                 
  Male                               11 201 (23.9)                        9 899 (24.6)    21 100 (24.2)
  Female                             11 511 (26.4)                        10 267 (27.2)   21 778 (26.8)
  **Age**                                                                                 
  \<65                               12 229 (26.1)                        10 251 (26.7)   22 480 (26.4)
  65--69                             6898 (24.8)                          6674 (26.8)     13 572 (25.8)
  70--74                             3585 (22.6)                          3241 (21.9)     6826 (22.3)
  **Screening episode type**                                                              
  Prevalent first time               5398 (25.4)                          3739 (25.8)     9137 (25.6)
  Incident                           14 985 (58.0)                        14 033(59.2)    29 018 (58.6)
  Prevalent previous non responder   2329 (5.4)                           2394 (6.0)      4723 (5.7)
  **Hub**                                                                                 
  Midlands and North-West            5899 (23.1)                          5231 (23.7)     11 130 (23.4)
  Southern                           6795 (29.4)                          5827 (30.5)     12 622 (29.9)
  London                             2196 (21.1)                          2444 (22.6)     4640 (21.9)
  North East                         2836 (22.2)                          2911 (23.7)     5747 (22.9)
  Eastern                            4986 (26.8)                          3753 (27.2)     8739 (27.0)
  **IMD quintile**                                                                        
  1 (least deprived)                 6601 (34.9)                          5522 (34.7)     12 123(34.8)
  2                                  5782 (29.7)                          5107 (30.8)     10 889 (30.2)
  3                                  4578 (25.0)                          4316 (26.8)     8894 (25.9)
  4                                  3436 (20.4)                          3104 (21.1)     6540 (20.7)
  5 (most deprived)                  2198 (13.3)                          2040 (14.1)     4238 (13.7)
  Total                              22 712 (25.1)                        20 166 (25.8)   42 878 (25.4)

###### Adjusted odds ratios and 95% confidence intervals or the effect of each variable on participation

                                     **Mulitivariate logistic regression results**[a](#t3-fn1){ref-type="fn"}   
  ---------------------------------- -------------------------------------------------------------------------- ------------
  **Trial arm**                                                                                                 
  Usual reminder                     1.00                                                                             
  Enhanced reminder                  1.07 (1.03--1.11)                                                           *P*\<0.001
  **Screening episode type**                                                                                    
  Prevalent first time               1.00                                                                             
  Incident                           4.55 (4.39--4.71)                                                           *P*\<0.001
  Prevalent previous non responder   0.20 (0.19--0.21)                                                           *P*\<0.001
  **Sex**                                                                                                       
  Male                               1.0                                                                              
  Female                             1.03 (1.00--1.06)                                                           *P*=0.024
  **Age**                                                                                                       
  59--64                             1.0                                                                              
  65--69                             0.85 (0.82--0.88)                                                           *P*\<0.001
  70--74                             0.66 (0.64--0.68)                                                           *P*\<0.001
  **Hub**                                                                                                       
  Midlands and NorthWest             1.00                                                                             
  Southern                           1.03 (0.99--1.08)                                                           *P*=0.123
  London                             0.88 (0.83--0.93)                                                           *P*\<0.001
  NorthEast                          0.96 (0.91--1.00)                                                           *P*=0.062
  Eastern                            0.98 (0.92--1.04)                                                           *P*=0.451
  **IMD quintile**                                                                                              
  1 (least deprived)                 1.00                                                                             
  2                                  0.84 (0.81--0.88)                                                           *P*\<0.001
  3                                  0.71 (0.68--0.74)                                                           *P*\<0.001
  4                                  0.58 (0.55--0.61)                                                           *P*\<0.001
  5 (most deprived)                  0.38 (0.36--0.40)                                                           *P*\<0.001

Adjusted for sex, age, screening episode type, IMD quintile, trial arm and hub.

###### Adjusted odds ratios and 95% confidence intervals for the effect of the enhanced reminder within each IMD quintile

                       **% Adequately screened**   **Adjusted logistic regression**[a](#t4-fn1){ref-type="fn"}                       
  -------------------- --------------------------- ------------------------------------------------------------- ------------------- ------------
  1 (least deprived)   34.9                        34.9                                                          1.00 (0.94--1.06)     *P*=0.98
  2                    29.7                        30.8                                                          1.04 (0.98--1.11)     *P*=0.2
  3                    25.0                        26.8                                                          1.13 (1.06--1.20)    *P*\<0.001
  4                    20.4                        21.1                                                          1.09 (1.02--1.17)    *P*=0.009
  5 (most deprived)    13.3                        14.1                                                          1.11 (1.04--1.20)    *P*=0.003

Adjusted for sex, age screening episode type and hub.

###### Effect of the enhanced reminder within subgroups

  **Variable**                       **OR (95% CI), enhanced** ***vs*** **usual reminder,**    **Significance of effect**   **Significance of interaction**[a](#t5-fn1){ref-type="fn"}
  ---------------------------------- -------------------------------------------------------- ---------------------------- ------------------------------------------------------------
  **Sex**                                                                                                                  
  Male                               1.04 (0.95--1.14)                                                  *P*=0.41                                     *P*=0.37
  Female                             1.04 (0.95--1.13)                                                  *P*=0.45                                     *P*=0.24
  **Age**                                                                                                                  
  \<65                               1.03 (0.96--1.11)                                                  *P*=0.44                                     *P*=0.06
  65--69                             1.11 (0.99--1.25)                                                  *P*=0.08                                     *P*=0.62
  70--74                             0.96 (0.83--1.10)                                                  *P*=0.56                                     *P*=0.79
  **Hub**                                                                                                                  
  Midlands and NorthWest             1.03 (0.96--1.11)                                                  *P*=0.38                                     *P*=0.99
  Southern                           1.05 (0.92--1.20)                                                  *P*=0.44                                    *P*=0.001
  London                             1.09 (0.93--1.28)                                                  *P*=0.29                                     *P*=0.90
  NorthEast                          1.09 (0.97--1.22)                                                  *P*=0.14                                     *P*=0.73
  Eastern                            1.02 (0.84--1.25)                                                  *P*=0.81                                     *P*=0.98
  **Screening episode type**                                                                                               
  Prevalent first time               1.02 (0.95--1.10)                                                  *P*=0.51                                     *P*=0.12
  Incident                           1.05 (0.97--1.12)                                                  *P*=0.21                                     *P*=0.05
  Prevalent previous non responder   1.12 (1.03--1.23)                                                 *P*=0.008                                     *P*=0.43

*P*-value for heterogeneity of effect of enhanced reminder by IMD expressed as a continuous score within each subgroup.

[^1]: These authors contributed equally to this work.

[^2]: Deceased.
